Kura OncologyKURA
Market Cap: $1.6B
About: Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Employees: 142
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
139% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $1.31M
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
5% more funds holding
Funds holding: 163 [Q1] → 171 (+8) [Q2]
10% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 61
2.17% less ownership
Funds ownership: 107.79% [Q1] → 105.62% (-2.17%) [Q2]
5% less capital invested
Capital invested by funds: $1.75B [Q1] → $1.66B (-$93.5M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JMP Securities Reni Benjamin 29% 1-year accuracy 10 / 35 met price target | 53%upside $32 | Market Outperform Reiterated | 12 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 103 / 273 met price target | 53%upside $32 | Buy Reiterated | 12 Aug 2024 |
Wedbush Robert Driscoll 56% 1-year accuracy 38 / 68 met price target | 77%upside $37 | Outperform Reiterated | 9 Aug 2024 |
Stifel Bradley Canino 47% 1-year accuracy 17 / 36 met price target | 24%upside $26 | Buy Maintained | 9 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 103 / 273 met price target | 53%upside $32 | Buy Reiterated | 24 Jun 2024 |